Molecular Diagnostics Market by Product & Service (Reagents, Kits, Instruments), Test Type (Lab, PoC), Technology (PCR, INAAT, NGS, ISH), Application (Infectious, Oncology, Genetic Testing), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2027
[302 Pages Report] The global molecular diagnostics market is projected to reach USD 30.2 billion by 2027, from USD 23.2 billion in 2022, at a CAGR of 5.4%. Market growth is driven by the rising technological advancements in molecular diagnostics and the growing awareness of early disease diagnosis in developing countries.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 Impact on the Molecular Diagnostics Market
Coronavirus disease (COVID-19) is a highly infectious disease. People infected with the COVID-19 virus experience mild to moderate respiratory illness. The COVID-19 strain was first identified in Wuhan City, Hubei Province, China, in December 2019. It has spread to many countries worldwide, with the WHO declaring it a pandemic since.
Molecular diagnostic testing for COVID-19 has been key to the global response to the pandemic.Since testing remains a crucial step in controlling the rapid spread of the disease, government organizations worldwide are supporting laboratories in streamlining COVID-19 testing procedures. In line with this, regulatory authorities utilized methods to speed up the approval of molecular diagnostic products. Moreover, major companies have undertaken strategic developments to introduce COVID-19 rapid tests and nullify the impact of COVID-19 on their operational capabilities, as diagnostic testing remains the backbone of the COVID-19 response, supporting containment efforts to mitigate the outbreak. Also, the severity of this crisis and increasing capacity issues associated with PCR-based testing accelerated the development of diagnostic solutions to meet the demands for mass testing. Major companies operating in this market scaled up their operations for testing and tracking COVID-19. The FDA approved various profiling tests, such as PCR testing panels and drugs, for emergency use in COVID-19 testing and diagnostics. Such developments played a key role in shaping the growth of the molecular diagnostics market.
Molecular Diagnostics Market Dynamics
Driver: Increasing prevalence of infectious diseases and cancer
Global outbreaks of deadly infectious diseases caused by pathogenic microorganisms have threatened public health worldwide and significantly motivated researchers to develop rapid and accurate detection methods for pathogens. Traditionally, culture-based techniques are considered gold standards for pathogen detection; however, the long turnaround time associated with these techniques due to overnight culturing and pathogen isolation limit their demand to a certain extent. In the past several years, the development and application of molecular diagnostic techniques have initiated a revolution in diagnosing and monitoring infectious diseases.
Opportunity: Growth opportunities in emerging countrie
Developing economies such as India, China, South Korea, Brazil, Turkey, Russia, and South Africa are expected to offer potential growth opportunities for major players operating in the molecular diagnostics market. This can be attributed to the high disease prevalence, large patient population, improving healthcare infrastructure, increasing disposable income, and growing medical tourism in these countries. In addition to the factors mentioned above, the Asia Pacific region has emerged as an adaptive and business-friendly hub due to relatively less stringent regulations and data requirements.
Restraint: Unfavorable reimbursement scenario
Inadequate reimbursements are a major factor restraining the growth of the molecular diagnostics market. Most diagnostic companies face a major challenge in commercializing their tests is getting Medicare and private health insurers to pay for them. In the US, Medicare revised its reimbursement mechanism for some IVD tests, including molecular tests, in 2018. Some of these molecular pathology tests do not have their own Healthcare Common Procedure Coding System (HCPCS) codes and are instead billed using unlisted codes. In such cases, Medicare Administrative Contractors (MACs) establish a payment amount for their local jurisdictions.
Challenge: Introduction of alternative technologies
The introduction of alternative technologies, such as those used in COVID-19 testing, can be challenging for the growth of the molecular diagnostics market. A majority of diagnostic tests for COVID-19 can be divided into polymerase chain reaction (PCR), serological, and antigen tests. PCR tests directly detect an antigen’s presence rather than the presence of the body’s immune response or antibodies. PCR tests can be very labor-intensive, with several stages at which errors may occur between sampling and analysis. It can take a few days to a week or longer to get results with PCR. Antibody tests, also known as serological tests, are used to determine the presence of a virus in a body by screening COVID-19 antibodies in the blood. Antibody tests can also assess past infections. The result is usually available in 15 minutes with antigen tests, and thus they are commonly referred to as rapid tests. Antigen tests are cheaper to manufacture than molecular tests owing to their simpler design. Thus, the introduction of alternative technologies might be challenging to the growth of the molecular diagnostics market.
Molecular Diagnostics Ecosystem/Market Map
To know about the assumptions considered for the study, download the pdf brochure
“In 2021, reagents & kits segment accounted for the largest share of the molecular diagnostics market, by product & service”
The global molecular diagnostics market is segmented into reagents & kits, instruments, and services & software based on product & service. The reagents & kits segment dominated the molecular diagnostics market in 2021. The frequent need for reagents & kits makes them a recurrent cost. This recurrent purchasing requirement is one of the key contributors to market growth.
“In 2021, lab tests segment accounted for the largest share in the market, by test type”
The molecular diagnostics market is segmented into lab tests and PoC tests by test type. The lab tests segment accounted for the largest share of the molecular diagnostics market in 2021. Factors such as the increasing need for automation and the rising incidence of various infectious diseases are driving the growth of this segment.
“In 2021, infectious disease diagnostics segment accounted for the largest share in the market, by application”
The molecular diagnostics market is segmented into infectious disease diagnostics, oncology testing, genetic testing, and other applications. In 2021, the infectious disease diagnostics segment accounted for the largest share of the global molecular diagnostics market. The large share of this segment can be attributed to the development of advanced assays for the diagnosis of different diseases & conditions and the increasing prevalence of infectious diseases.
“In 2021, North America accounted for the largest share of the molecular diagnostics market ”
The global molecular diagnostics market is segmented into five major regions namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest market share of the molecular diagnostics market in 2021. Factors such as the increasing prevalence of infectious diseases & cancer, the increasing healthcare spending, and the presence of many leading national clinical laboratoriesare contributing to the large share of this regional segment.
Key Market Players
The molecular diagnostics market is dominated by players such as F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), PerkinElmer, Inc. (US), Thermo Fisher Scientific, Inc. (US), and Abbott Laboratories (US).
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
2020–2027 |
|
Base year considered |
2021 |
|
Forecast period |
2022–2027 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Product & service, test type, technology, application, end user, and region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
|
Companies covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Abbott Laboratories (US), bioMérieux SA (France), QIAGEN N.V. (Netherlands), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), Illumina, Inc. (US), Becton, Dickinson and Company (US), Grifols, S.A. (Spain), Quidel Corporation (US), Agilent Technologies, Inc. (US), DiaSorin S.p.a. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), MDx Health (Belgium), Biocartis NV (Belgium), TBG Diagnostics Limited (Australia), HTG Molecular Diagnostics, Inc. (US), Vela Diagnostics (Singapore), Amoy Diagnostics Co., Ltd. (China), ELITechGroup (France), Molbio Diagnostics Pvt. Ltd. (India), Savyon Diagnostics (Israel), Abacus Diagnostica Oy (Finland), and geneOmbio Technologies Pvt. Ltd. (India) |
This report categorizes the molecular diagnostics market into the following segments and subsegments:
By Product & Service
- Reagents & Kits
- Instruments
- Services & Software
By Test Type
- Lab Tests
- PoC Tests
By Technology
- Polymerase Chain Reaction (PCR)
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- DNA Sequencing & Next- generation Sequencing (NGS)
- In Situ Hybridization (ISH)
- DNA Microarrays
- Other Technologies
By Application
- Infectious Disease Diagnostics
- COVID-19
- Hepatitis
- HIV
- CT/NG
- HAI
- HPV
- Tuberculosis
- Influenza
- Other Infectious Diseases
- Oncology Testing
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancers
- Genetic Testing
- Other Applications
By End User
- Diagnostic Laboratories
- Hospitals & Clinics
- Other End Users
By Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Russia
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Recent Developments:
- In September 2021, F. Hoffmann-La Roche Ltd. (Switzerland) announced the acquisition of TIB Molbiol (Germany) to expand its PCR test portfolio with a wide range of assays for infectious diseases.
- In June 2021, QIAGEN N.V.(Netherlands) partnered with Verogen (US) to broaden its portfolio in NGS technologies.
- In June 2021, Hologic, Inc. (US) acquired Mobidiag Oy (Finland), an innovator in acute care molecular diagnostic testing. This acquisition will aid in expanding Hologic’s molecular diagnostics product portfolio.
- In November 2020, Hologic, Inc. (US) received additional FDA approval for the AptimaHIV-1 Quant Dx Assay for use as an aid in the diagnosis of HIV infection.
Frequently Asked Questions (FAQ):
What are the recent trends affecting the molecular diagnostics market?
Recent trends affecting the molecular diagnostics market are the COVID-19 outbreak, increasing prevalence of infectious diseases and cancer, growing awareness of early disease diagnosis in developing countries, and increasing use of PoC diagnostic tests
What are the major types of molecular diagnostic technologies used?
The molecular diagnostics market is broadly segmented into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), in situ hybridization (ISH), DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies.
In 2021, PCR segment accounted for the largest share of the molecular diagnostics market, mainly due to the growing use of RT-PCR in COVID-19 tests and automation of PCR instruments.
Who are the key players in the molecular diagnostics market?
The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Abbott Laboratories (US), bioMérieux SA (France), QIAGEN N.V. (Netherlands), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), Illumina, Inc. (US), Becton, Dickinson and Company (US), Grifols, S.A. (Spain), Quidel Corporation (US), Agilent Technologies, Inc. (US), and DiaSorin S.p.a. (Italy).
Who are the major end users of molecular diagnostics?
Based on end users, the molecular diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, and other end users. In 2021, diagnostic laboratories accounted for the largest market share of the molecular diagnostics market, mainly due to the increasing test volumes for infectious diseases & cancer and strengthening healthcare infrastructures for efficient disease diagnosis & treatment.
Which region is lucrative for the molecular diagnostics market?
Like China, Japan, and India, the emerging economies in the Asia Pacific region will be the lucrative markets for molecular diagnostics. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 36)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.3 MARKETS COVERED
1.3.1 MOLECULAR DIAGNOSTICS MARKET
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 42)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 ASSUMPTIONS FOR THE STUDY
2.7 LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RISK ASSESSMENT
2.9.1 RISK ASSESSMENT: MOLECULAR DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY (Page No. - 55)
FIGURE 8 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 60)
4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
FIGURE 14 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027
FIGURE 15 REAGENTS & KITS WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2022 VS. 2027
FIGURE 16 THE LAB TESTS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.4 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027
FIGURE 17 THE PCR SEGMENT IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.5 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022 VS. 2027
FIGURE 18 THE INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.6 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027
FIGURE 19 THE DIAGNOSTIC LABORATORIES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.7 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 64)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of infectious diseases and cancer
TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025
TABLE 2 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
5.2.1.2 Rising focus on R&D and growing funding in molecular diagnostics
5.2.1.3 Growing awareness of early disease diagnosis in developing countries
5.2.1.4 Rising technological advancements in molecular diagnostics
5.2.1.5 Increasing use of PoC diagnostic tests
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.2.2 High cost of instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics
5.2.3.2 Growth opportunities in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape
5.2.4.2 Operational barriers
5.2.4.3 Introduction of alternative technologies
5.2.5 IMPACT OF COVID-19 ON THE MOLECULAR DIAGNOSTICS MARKET
5.3 PRICING ANALYSIS
TABLE 3 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022)
5.4 PATENT ANALYSIS
FIGURE 22 LIST OF MAJOR PATENTS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 23 VALUE CHAIN ANALYSIS OF THE MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 24 MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET MAP
FIGURE 25 MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM/MARKET MAP
5.7.1 MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 REGULATORY LANDSCAPE
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
5.9.3.3 India
5.9.4 LATIN AMERICA
5.9.4.1 Brazil
5.9.4.2 Mexico
5.9.5 MIDDLE EAST
5.9.6 AFRICA
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2017–2021 (USD million)
5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2017–2021 (USD million)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES & EVENTS IN 2022–2023
TABLE 10 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13.1 REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO THE COVID-19 PANDEMIC
FIGURE 26 REVENUE SHIFT IN THE MOLECULAR DIAGNOSTICS MARKET
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS, BY END USER
FIGURE 27 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS, BY END USER
TABLE 11 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS, BY END USER (%)
5.14.2 BUYING CRITERIA
FIGURE 28 KEY BUYING CRITERIA, BY END USER
TABLE 12 KEY BUYING CRITERIA, BY END USER
5.15 CASE STUDIES
FIGURE 29 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA
6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 92)
6.1 INTRODUCTION
TABLE 13 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 14 PRICES OF MOLECULAR DIAGNOSTIC PRODUCTS (2021)
6.2 REAGENTS & KITS
6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS—A KEY FACTOR PROPELLING MARKET GROWTH
TABLE 15 MOLECULAR DIAGNOSTIC REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO BOOST THE DEMAND FOR MOLECULAR DIAGNOSTIC INSTRUMENTS
TABLE 16 KEY INSTRUMENTS AVAILABLE IN THE MARKET
TABLE 17 MOLECULAR DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.4 SERVICES & SOFTWARE
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS IN THE MOLECULAR DIAGNOSTICS MARKET TO DRIVE GROWTH IN THIS MARKET SEGMENT
TABLE 18 MOLECULAR DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY REGION, 2020–2027 (USD MILLION)
7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 98)
7.1 INTRODUCTION
TABLE 19 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)
7.2 LAB TESTS
7.2.1 HIGH BURDEN OF COVID-19 TO DRIVE MARKET GROWTH
TABLE 20 MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION, 2020–2027 (USD MILLION)
7.3 POC TESTS
7.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE SEGMENTAL GROWTH IN THE COMING YEARS
TABLE 21 MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2020–2027 (USD MILLION)
8 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 102)
8.1 INTRODUCTION
8.1.1 PRIMARY NOTES
8.1.1.1 Key industry insights
TABLE 22 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
8.2 POLYMERASE CHAIN REACTION (PCR)
8.2.1 GROWING USE OF PCR IN PROTEOMICS AND GENOMICS MAKES THIS THE LARGEST MARKET SEGMENT
TABLE 23 MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2020–2027 (USD MILLION)
8.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
8.3.1 COST BENEFITS OF INAAT TO DRIVE MARKET GROWTH
TABLE 24 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2020–2027 (USD MILLION)
8.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
8.4.1 INCREASING USE OF NGS IN CANCER DIAGNOSIS TO FUEL GROWTH IN THIS MARKET SEGMENT
TABLE 25 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2020–2027 (USD MILLION)
8.5 IN SITU HYBRIDIZATION (ISH)
8.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS— A KEY FACTOR DRIVING GROWTH
TABLE 26 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2020–2027 (USD MILLION)
8.6 DNA MICROARRAYS
8.6.1 INTRODUCTION OF DNA MICROARRAYS HAS ACCELERATED GENE EXPRESSION AND DISEASE DIAGNOSIS
TABLE 27 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2020–2027 (USD MILLION)
8.7 OTHER TECHNOLOGIES
TABLE 28 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
9 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 111)
9.1 INTRODUCTION
TABLE 29 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
9.2 INFECTIOUS DISEASE DIAGNOSTICS
TABLE 30 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 31 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
9.2.1 COVID-19
9.2.1.1 Growing burden of COVID-19 is a key factor driving market growth
TABLE 32 DISTRIBUTION OF TOTAL NUMBER OF CASES, BY COUNTRY
TABLE 33 MOLECULAR DIAGNOSTICS MARKET FOR COVID-19 TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 34 MOLECULAR DIAGNOSTICS MARKET FOR COVID-19 TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.2 HEPATITIS
9.2.2.1 Increasing adoption of advanced technologies for the diagnosis of hepatitis B to drive growth in this segment
TABLE 35 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 36 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.3 HIV
9.2.3.1 High global prevalence of HIV will drive the need for molecular diagnostic tests
TABLE 37 MOLECULAR DIAGNOSTICS MARKET FOR HIV TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 38 MOLECULAR DIAGNOSTICS MARKET FOR HIV TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.4 HAI
9.2.4.1 Rising burden of MRSA infections and the increasing adoption of technologically advanced HAI diagnostic tests will likely drive market growth
TABLE 39 MOLECULAR DIAGNOSTICS MARKET FOR HAI TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 40 MOLECULAR DIAGNOSTICS MARKET FOR HAI TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.5 CT/NG
9.2.5.1 CT/NG infections are the most common STDs worldwide—a key factor driving market growth
TABLE 41 MOLECULAR DIAGNOSTICS MARKET FOR CT/NG TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 42 MOLECULAR DIAGNOSTICS MARKET FOR CT/NG TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.6 HPV
9.2.6.1 Technological advancements such as rapid HPV diagnostics drive growth in this segment
TABLE 43 MOLECULAR DIAGNOSTICS MARKET FOR HPV TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 44 MOLECULAR DIAGNOSTICS MARKET FOR HPV TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.7 TUBERCULOSIS
9.2.7.1 Increasing burden of TB globally to propel the demand for MDx tests
TABLE 45 MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 46 MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.8 INFLUENZA
9.2.8.1 Rising focus on containing the spread of influenza to propel growth in this segment
TABLE 47 MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 48 MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.9 OTHER INFECTIOUS DISEASES
TABLE 49 MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
9.3 ONCOLOGY TESTING
TABLE 50 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 51 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
9.3.1 BREAST CANCER
9.3.1.1 Increasing prevalence of breast cancer is a key driver for market growth
TABLE 52 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 53 MOLECULAR DIAGNOSTIC MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION)
9.3.2 COLORECTAL CANCER
9.3.2.1 Rising focus on the development of companion diagnostic assays for colorectal cancer drives market growth
TABLE 54 MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2027 (USD MILLION)
9.3.3 LUNG CANCER
9.3.3.1 Increasing research for lung cancer biomarkers to drive market growth
TABLE 55 MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2020–2027 (USD MILLION)
9.3.4 PROSTATE CANCER
9.3.4.1 Advancements in genomic technologies for the development of new biomarkers will drive the market growth
TABLE 56 MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION)
9.3.5 OTHER CANCERS
TABLE 57 GLOBAL CANCER INCIDENCE, 2020
TABLE 58 MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION)
9.4 GENETIC TESTING
9.4.1 GENETIC TESTING ENABLES THE DIAGNOSIS OF VARIOUS DISEASES—A KEY FACTOR DRIVING MARKET GROWTH
TABLE 59 MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.5 OTHER APPLICATIONS
TABLE 60 MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
10 MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 133)
10.1 INTRODUCTION
TABLE 61 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 DIAGNOSTIC LABORATORIES
10.2.1 INCREASING OUTSOURCING OF ACTIVITIES TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS TO DRIVE MARKET GROWTH
TABLE 62 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
10.3 HOSPITALS & CLINICS
10.3.1 INCREASING NUMBER OF HOSPITALS AND GOVERNMENT INVESTMENTS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 63 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
10.4 OTHER END USERS
TABLE 64 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
11 MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 138)
11.1 INTRODUCTION
TABLE 65 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 66 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 68 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 69 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 70 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 71 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 72 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 Increasing prevalence of infectious diseases and cancer to drive market growth in the US
TABLE 73 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 74 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 75 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 76 US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 77 US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 78 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Availability of funding for genomics research makes Canada a sizeable market for molecular diagnostics
TABLE 79 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 80 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 81 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 82 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 83 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 84 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 85 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 86 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 87 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 88 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 89 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 90 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 91 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Increasing healthcare expenditure to drive market growth in Germany
TABLE 92 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 93 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 94 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 95 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.2 UK
11.3.2.1 Growing number of accredited diagnostic laboratories propels market growth for molecular diagnostics in the UK
TABLE 98 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 99 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 100 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 101 UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 102 UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Rising R&D expenditure in France to drive market growth
TABLE 104 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 105 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 106 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 107 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 108 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
TABLE 110 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 111 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 112 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 113 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 114 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 115 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.5 RUSSIA
11.3.5.1 Increasing access to quality healthcare will support market growth in Russia
TABLE 116 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 117 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 118 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 119 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 120 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 121 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Growing demand for genetic testing in Spain to create major growth opportunities for market players
TABLE 122 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 123 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 124 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 125 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 126 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 127 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 128 ROE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 129 ROE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 130 ROE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 131 ROE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 132 ROE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 133 ROE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 31 APAC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 134 APAC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 135 APAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 136 APAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 137 APAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 138 APAC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 139 APAC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 140 APAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth
TABLE 141 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 142 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 143 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 144 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 145 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
TABLE 147 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 148 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 149 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 150 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 151 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 152 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth
TABLE 153 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 154 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 155 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 156 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 157 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 158 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.4 AUSTRALIA
11.4.4.1 High prevalence of infectious diseases makes Australia a relatively large market in the APAC
TABLE 159 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 160 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 161 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 162 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 163 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 164 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.5 REST OF ASIA PACIFIC
TABLE 165 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 166 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 167 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 168 ROAPAC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 169 ROAPAC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 170 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
TABLE 171 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 172 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 173 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 174 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 175 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 176 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Improving healthcare infrastructure to drive the growth of the molecular diagnostics market in Brazil
TABLE 178 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 179 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 180 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 181 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 182 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 183 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.2 MEXICO
11.5.2.1 Improving accessibility and affordability of healthcare services in Mexico makes it a favorable market for molecular diagnostics
TABLE 184 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 185 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 186 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 187 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 188 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 189 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 190 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 191 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 192 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 193 ROLATAM: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 194 ROLATAM: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 195 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
TABLE 196 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 197 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 198 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 199 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 200 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 201 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 215)
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE MOLECULAR DIAGNOSTICS MARKET
TABLE 202 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR DIAGNOSTIC MANUFACTURING COMPANIES
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 32 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE MOLECULAR DIAGNOSTICS MARKET
12.4 MARKET SHARE ANALYSIS
12.4.1 MOLECULAR DIAGNOSTICS MARKET
FIGURE 33 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2021)
TABLE 203 MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION
12.4.2 MOLECULAR DIAGNOSTICS MARKET SHARE & RANKING ANALYSIS, BY TECHNOLOGY
12.4.2.1 Polymerase chain reaction (PCR)
FIGURE 34 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE FOR PCR, BY KEY PLAYER (2021)
12.4.2.2 DNA sequencing and NGS
FIGURE 35 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE FOR DNA SEQUENCING & NGS, BY KEY PLAYER (2021)
12.4.2.3 Isothermal nucleic acid amplification technology (INAAT)
TABLE 204 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INAAT, BY KEY PLAYER, 2021
12.4.2.4 In situ hybridization (ISH)
TABLE 205 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR ISH, BY KEY PLAYER, 2021
12.4.3 MOLECULAR DIAGNOSTICS MARKET RANKING ANALYSIS, BY APPLICATION
12.4.3.1 Infectious diseases
TABLE 206 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INFECTIOUS DISEASES, BY KEY PLAYER, 2021
12.4.3.2 COVID-19
TABLE 207 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR COVID-19, BY KEY PLAYER, 2021
12.5 COMPANY EVALUATION QUADRANT
12.5.1 LIST OF EVALUATED VENDORS
12.5.2 STARS
12.5.3 EMERGING LEADERS
12.5.4 PERVASIVE PLAYERS
12.5.5 PARTICIPANTS
FIGURE 36 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 37 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
12.7 COMPETITIVE BENCHMARKING
12.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
FIGURE 38 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE MOLECULAR DIAGNOSTICS MARKET
TABLE 208 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 209 COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 210 COMPANY REGIONAL FOOTPRINT
TABLE 211 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
12.8 COMPETITIVE SCENARIO
12.8.1 PRODUCT LAUNCHES
TABLE 212 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
12.8.2 DEALS
TABLE 213 KEY DEALS
13 COMPANY PROFILES (Page No. - 230)
13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 F. HOFFMANN-LA ROCHE LTD
TABLE 214 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
13.1.2 HOLOGIC, INC.
TABLE 215 HOLOGIC, INC.: BUSINESS OVERVIEW
FIGURE 40 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
13.1.3 PERKINELMER, INC.
TABLE 216 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 41 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
13.1.4 ABBOTT LABORATORIES
TABLE 217 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
13.1.5 THERMO FISHER SCIENTIFIC, INC.
TABLE 218 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
13.1.6 QIAGEN N.V.
TABLE 219 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 44 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
13.1.7 SIEMENS HEALTHINEERS AG
TABLE 220 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
13.1.8 BIOMÉRIEUX SA
TABLE 221 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 46 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
13.1.9 MYRIAD GENETICS, INC.
TABLE 222 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2021)
13.1.10 DANAHER CORPORATION
TABLE 223 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 ILLUMINA, INC.
TABLE 224 ILLUMINA, INC.: COMPANY OVERVIEW
13.2.2 BECTON, DICKINSON AND COMPANY
TABLE 225 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
13.2.3 GRIFOLS, S.A.
TABLE 226 GRIFOLS, S.A.: COMPANY OVERVIEW
13.2.4 QUIDEL CORPORATION
TABLE 227 QUIDEL CORPORATION: COMPANY OVERVIEW
13.2.5 AGILENT TECHNOLOGIES, INC.
TABLE 228 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
13.2.6 DIASORIN S.P.A.
TABLE 229 DIASORIN S.P.A.: COMPANY OVERVIEW
13.2.7 EXACT SCIENCES CORPORATION
TABLE 230 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW
13.2.8 GENETIC SIGNATURES
TABLE 231 GENETIC SIGNATURES: COMPANY OVERVIEW
13.2.9 MDXHEALTH
TABLE 232 MDXHEALTH: COMPANY OVERVIEW
13.2.10 HTG MOLECULAR DIAGNOSTICS, INC.
TABLE 233 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY OVERVIEW
13.2.11 BIOCARTIS NV
TABLE 234 BIOCARTIS NV: COMPANY OVERVIEW
13.2.12 TBG DIAGNOSTICS LIMITED
TABLE 235 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
13.2.13 VELA DIAGNOSTICS
TABLE 236 VELA DIAGNOSTICS: COMPANY OVERVIEW
13.2.14 AMOY DIAGNOSTICS CO., LTD.
TABLE 237 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
13.2.15 ELITECHGROUP
TABLE 238 ELITECHGROUP: COMPANY OVERVIEW
13.2.16 MOLBIO DIAGNOSTICS PVT. LTD.
TABLE 239 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
13.2.17 SAVYON DIAGNOSTICS
TABLE 240 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
13.2.18 ABACUS DIAGNOSTICA OY
TABLE 241 ABACUS DIAGNOSTICA OY.: COMPANY OVERVIEW
13.2.19 GENEOMBIO TECHNOLOGIES PVT. LTD.
TABLE 242 GENEOMBIO TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW
14 APPENDIX (Page No. - 294)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the molecular diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the molecular diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the molecular diagnostics market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Global Molecular Diagnostics Market Size: Top-Down Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, segment, and forecast the global molecular diagnostics market, by product & service, test type, technology, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall molecular diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Country Information
- Molecular diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa
Company profiles
- Additional five company profiles of players operating in the molecular diagnostics market.
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Molecular Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Molecular Diagnostics Market
•The molecular diagnostics market is segmented into lab tests and PoC tests by test type. The lab tests segment accounted for the largest share of the molecular diagnostics market in 2021. Factors such as the increasing need for automation and the rising incidence of various infectious diseases are driving the growth of this segment. •Molecular diagnostic reagents include disease-specific kits and general reagents used during infectious disease diagnosis and pathogen screening. Laboratory technicians utilize specific disease diagnostic kits for earlier and more accurate identification of specific pathogen strains in a patient sample. General reagents are key components of a majority of conventional molecular diagnostic procedures. • Companies are now launching rapid kits and reagents to detect the novel coronavirus, which is further fueling the growth of this market segment. Regional authorities have also been actively engaged in providing emergency approvals for the use of these kits. In September 2020, Danaher Corporation (US) received Emergency Use Authorization (EUA) from the US Food & Drug Administration (FDA) for its Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for the qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample. In March 2020, QIAGEN N.V. (Netherlands) received FDA approval for its QIAstat-Dx test kit to detect coronavirus.
• Due to covid, there was an increase in the demand for immunodiagnostics and molecular testing, which was regarded as the gold standard for diagnosing infectious diseases, leading to the increased sales of related consumables and kits. During the pandemic era, revenue growth for key players was majorly driven by the sales of COVID-19 diagnostic tests. The dominant model of laboratory testing throughout the world remains the centralized laboratory that uses automated analytical testing methods to detect target analytes. This trend is well established in clinical chemistry and haematology disciplines and is now extending to other areas, including immunoassays and molecular diagnostics. Reagents & kits segment accounted for the largest share in the IVD market and Oncology segment is expected to witness the fastest growth in the forecast period. With 30,000+ partners, technologies, and use-cases as the primary levers, we have deep understanding of IVD ecosystem. We offer more than 2X coverage throughout the IVD curve as compared to our competitors.